JP2014502156A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502156A5
JP2014502156A5 JP2013541211A JP2013541211A JP2014502156A5 JP 2014502156 A5 JP2014502156 A5 JP 2014502156A5 JP 2013541211 A JP2013541211 A JP 2013541211A JP 2013541211 A JP2013541211 A JP 2013541211A JP 2014502156 A5 JP2014502156 A5 JP 2014502156A5
Authority
JP
Japan
Prior art keywords
peptide
peptide according
isolated
vector
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013541211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502156A (ja
JP6069212B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2011/050460 external-priority patent/WO2012072088A1/en
Publication of JP2014502156A publication Critical patent/JP2014502156A/ja
Publication of JP2014502156A5 publication Critical patent/JP2014502156A5/ja
Application granted granted Critical
Publication of JP6069212B2 publication Critical patent/JP6069212B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013541211A 2010-12-02 2011-12-02 ペプチド骨格設計 Expired - Fee Related JP6069212B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10193479.2 2010-12-02
EP10193479 2010-12-02
US201161475965P 2011-04-15 2011-04-15
US61/475,965 2011-04-15
PCT/DK2011/050460 WO2012072088A1 (en) 2010-12-02 2011-12-02 Peptide scaffold design

Publications (3)

Publication Number Publication Date
JP2014502156A JP2014502156A (ja) 2014-01-30
JP2014502156A5 true JP2014502156A5 (https=) 2014-12-18
JP6069212B2 JP6069212B2 (ja) 2017-02-01

Family

ID=44022075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541211A Expired - Fee Related JP6069212B2 (ja) 2010-12-02 2011-12-02 ペプチド骨格設計

Country Status (10)

Country Link
US (2) US9550811B2 (https=)
EP (1) EP2646459B1 (https=)
JP (1) JP6069212B2 (https=)
CN (1) CN103282375B (https=)
AU (1) AU2011335551B2 (https=)
CA (1) CA2819416C (https=)
EA (1) EA025152B1 (https=)
NZ (1) NZ611176A (https=)
WO (1) WO2012072088A1 (https=)
ZA (1) ZA201304017B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
IN2014KN02774A (https=) 2012-06-06 2015-05-08 Bionor Immuno As
JP6310909B2 (ja) * 2012-06-06 2018-04-11 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) * 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
WO2016021605A1 (ja) * 2014-08-04 2016-02-11 日東電工株式会社 Ｃｔｌのアポトーシスを抑制するまたｃｔｌの誘導抑制を阻害するワクチン医薬組成物
CN107074910B (zh) * 2014-08-17 2022-02-18 塞里维瑞疗法公司 高级大分子转导域序列、编码其的多核苷酸及其用途
US20160060314A1 (en) 2014-08-27 2016-03-03 Daewoong Jo Development of a Protein-Based Biotherapeutic Agent That Penetrates Cell-Membrane and Induces Anti-Tumor Effect in Solid Tumors - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Tumor Compositions Comprising the Same
CN107847544B (zh) * 2015-07-20 2021-10-15 小利兰·斯坦福大学董事会 用多聚体结合试剂检测细胞表型和定量
US20170029798A1 (en) 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
EP3334755B1 (en) 2015-08-10 2020-04-08 Cellivery Therapeutics, Inc. Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof
EP3334756B1 (en) 2015-08-10 2020-06-17 Cellivery Therapeutics, Inc. Improved cell-permeable cre (icp-cre) recombinant protein and use thereof
WO2017030323A1 (en) 2015-08-18 2017-02-23 Cellivery Therapeutics, Inc. Cell-permeable (cp)-δsocs3 recombinant protein and uses thereof
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
CA3030855A1 (en) 2016-07-18 2018-01-25 President And Fellows Of Harvard College Methods and compositions relating to covalently circularized nanodiscs
US20200131231A1 (en) 2017-02-17 2020-04-30 Oxford University Innovation Limited Cell penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
CA3118412A1 (en) * 2018-11-02 2020-05-07 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Cell-penetrating peptide based on influenza virus m2 protein
CN113453723A (zh) 2018-12-07 2021-09-28 牛津大学科技创新有限公司 接头
EP4593803A2 (en) * 2022-09-30 2025-08-06 Capricor, Inc. Combination exosomal immunogenic compositions and methods
CN116077686B (zh) * 2022-12-15 2025-06-27 苏州智核生物医药科技有限公司 可酶切Linker及其用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4209215A1 (de) 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
FI945483A7 (fi) 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
EP0992580B1 (en) 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU697171B2 (en) 1994-04-08 1998-10-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis C virus core peptide for stimulation of cytotoxic T lymphocytes and diagnosis of HCV exposure
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6719976B1 (en) * 1996-03-10 2004-04-13 Meiji Milk Products Co., Ltd. Peptide-based immunotherapeutic agent for treating allergic diseases
DE69733352T2 (de) 1996-03-21 2006-04-27 Epimmune, Inc., San Diego Hla-a2.1 bindende peptide und deren verwendung
CA2250723C (en) 1996-05-24 2012-07-17 Chiron Corporation Multiple epitope fusion protein
US6566330B1 (en) 1996-10-22 2003-05-20 Medical University Of South Carolina Foundation Research Development Positively charged non-natural amino acids, methods of making and using thereof in peptides
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
EP1200109A4 (en) 1999-07-19 2005-06-15 Epimmune Inc USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
US6258932B1 (en) * 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
US20020076415A1 (en) 1999-12-14 2002-06-20 Jing-Hsiung Ou Hepatitis C virus gene products
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
AU2000273396A1 (en) 2000-09-01 2002-03-22 Epimmune, Inc. Hla binding peptides and their uses
EP1195381A1 (de) 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
GB0026094D0 (en) 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
FR2824326B1 (fr) 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
AUPR593101A0 (en) 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
FR2839722A1 (fr) 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
ATE356385T1 (de) 2002-06-10 2007-03-15 Algonomics N V Verfahren zur vorhersage der bindungsaffinität der mhc-peptid-komplexe
EP2402026A3 (en) 2002-09-13 2012-04-18 Intercell AG Method for isolating hepatitis C virus peptides
EP1584627B1 (en) 2003-01-15 2009-10-07 International Institute of Cancer Immunology, Inc. Dimerized peptide
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
EP1652858A1 (en) 2004-10-28 2006-05-03 Innogenetics N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
CA2610667A1 (en) 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
WO2008107400A1 (en) * 2007-03-02 2008-09-12 Genimmune N.V. Hcv polyepitope construct and uses thereof
ES2482192T3 (es) 2007-05-31 2014-08-01 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Vacunación intradérmica del péptido de HPV
EP2176420B1 (en) 2007-07-13 2018-02-14 University of Pittsburgh - Of the Commonwealth System of Higher Education Virus derived antimicrobial peptides
US20100019186A1 (en) * 2008-07-25 2010-01-28 Eaton Corporation Engine valve assembly with valve can mountable to an engine cover
CN101412747B (zh) 2008-10-21 2011-04-20 中国药科大学 新型穿膜肽及其用途
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
US20120121537A1 (en) * 2009-01-12 2012-05-17 Chaomin Sun Methods and Compositions for Inhibiting Hepatitis C Virus Replication

Similar Documents

Publication Publication Date Title
JP2014502156A5 (https=)
van Riet et al. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
JP2014534202A5 (https=)
JP2015524422A5 (https=)
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2015501840A5 (https=)
JP2014503206A5 (https=)
JP2015521206A5 (https=)
JP2014530010A5 (https=)
JP2016534034A5 (https=)
JP2014507144A5 (ja) 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
RU2019139064A (ru) Композиции и способы для лечения цитомегаловируса
JP2016506416A5 (https=)
JP2012501959A5 (https=)
JP2018148890A5 (https=)
IL276210B2 (en) Mers-cov vaccine
JP2015214545A5 (https=)
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
JP2014507146A5 (https=)
JP2012515557A5 (https=)
JP2015529678A5 (https=)
JP2015506705A5 (https=)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
JP2014519817A5 (https=)